TransMedics Group, Inc.
General ticker "TMDX" information:
- Sector: Health Care
- Industry: Health Care Equipment & Supplies
- Capitalization: $3.3B (TTM average)
TransMedics Group, Inc. follows the US Stock Market performance with the rate: 48.1%.
Estimated limits based on current volatility of 3.7%: low 137.40$, high 148.01$
Factors to consider:
- Total employees count: 728 (+24.7%) as of 2024
- Top business risk factors: Dependence on key customers, Operational and conduct risks, Cybersecurity threats, Supply chain disruptions, Reputation and brand risks
- Current price 31.5% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [51.85$, 105.40$]
- 2025-12-31 to 2026-12-31 estimated range: [50.94$, 103.10$]
Financial Metrics affecting the TMDX estimates:
- Negative: with PPE of 61.0 at the end of fiscal year the price was very high
- Positive: 7.86 < Operating profit margin, % of 8.49
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 4.22
- Positive: -14.38 < Investing cash flow per share per price, % of -6.31
- Negative: Industry earnings per price (median), % of -3.67 <= 0
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0.70 <= 0.79
- Positive: Industry inventory ratio change (median), % of -1.44 <= -0.15
- Positive: 18.93 < Shareholder equity ratio, % of 28.43 <= 41.86
Short-term TMDX quotes
Long-term TMDX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $93.46MM | $241.62MM | $441.54MM |
| Operating Expenses | $124.90MM | $270.35MM | $404.04MM |
| Operating Income | $-31.44MM | $-28.73MM | $37.50MM |
| Non-Operating Income | $-4.73MM | $2.06MM | $-1.72MM |
| Interest Expense | $3.73MM | $10.79MM | $14.41MM |
| R&D Expense | $26.81MM | $63.27MM | $55.97MM |
| Income(Loss) | $-36.16MM | $-26.67MM | $35.78MM |
| Taxes | $0.07MM | $-1.64MM | $0.32MM |
| Profit(Loss)* | $-36.23MM | $-25.03MM | $35.46MM |
| Stockholders Equity | $187.38MM | $137.20MM | $228.60MM |
| Inventory | $20.61MM | $44.23MM | $46.55MM |
| Assets | $277.15MM | $706.05MM | $804.08MM |
| Operating Cash Flow | $-45.82MM | $-13.03MM | $48.80MM |
| Capital expenditure | $11.91MM | $179.06MM | $129.74MM |
| Investing Cash Flow | $54.51MM | $-193.95MM | $-129.30MM |
| Financing Cash Flow | $167.93MM | $400.42MM | $22.87MM |
| Earnings Per Share** | $-1.23 | $-0.77 | $1.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.